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Abstract
Purpose of review—Obesity is a major risk factor for the development of de novo chronic 
kidney disease (CKD). However, once kidney disease is acquired, obesity is paradoxically linked 
with greater survival, especially in those with advanced CKD. This review examines current 
evidence for obesity as a risk factor for incident CKD, studies of obesity and mortality across 
various CKD populations, and potential mechanisms underlying the ‘obesity paradox’ in kidney 
disease.
Recent findings—Large cohort studies show that overweight body habitus, especially in the 
context of metabolic syndrome, is associated with higher risk of incident CKD. Emerging data 
also suggest weight-loss interventions retard or reverse early CKD progression, whereas in 
hemodialysis patients weight-loss paradoxically heralds poor outcomes. Although the 
pathogenesis of CKD in obesity remains unclear, studies indicate that excess body fat leads to 
kidney disease via indirect and direct mechanisms. Meta-analyses suggest that overweight and 
obese BMI ranges are counterintuitively associated with lower mortality in advanced predialysis 
and dialysis-dependent CKD patients, whereas a pooled analysis observed that higher 
pretransplantation BMI was associated with higher mortality in kidney transplantation recipients.
Summary—In addition to its role as a risk factor for de novo CKD, there appears to be a 
consistent association between obesity and lower mortality in those with established CKD, 
particularly among hemodialysis patients, suggesting that the reverse epidemiology of obesity is 
biologically plausible.
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Introduction
In the United States, obesity affects more than one-third (35% or 78.6 million) of the adult 
population and accounts for over $140 billion in annual medical costs [1,2▪]. In the general 
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population, obesity accelerates death risk and has been linked with many comorbidities, such 
as cardiovascular disease, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep 
apnea, fatty liver and biliary disease, osteoarthritis, various malignancies, including kidney 
cancer, neuropsychiatric complications, and impaired health-related quality of life [3–6,7▪▪,
8,9].
Obesity is also a major risk factor for the development and progression of chronic kidney 
disease (CKD) [10–12]. However, past studies examining the association between obesity 
and outcomes in the CKD population, including those receiving dialysis and kidney 
transplantation, are complex and somewhat controversial [7▪▪,13]. The current body of 
evidence suggests that once CKD is established, obesity is paradoxically associated with 
greater survival, particularly among those receiving hemodialysis, a phenomenon which has 
been coined the ‘obesity paradox’ or ‘reverse epidemiology’ [6]. Although the underlying 
mechanisms of the obesity paradox remain unclear, these observations have been markedly 
consistent across numerous studies, suggesting scientific plausibility. In this review, we will 
summarize existing evidence of obesity as a risk factor for incident CKD, including 
underlying pathophysiologic mechanisms; provide an overview of studies examining obesity 
and CKD-related complications across the nondialysis dependent CKD (NDD-CKD), 
hemodialysis, peritoneal dialysis, and kidney transplantation populations; examine putative 
causes by which obesity may counterintuitively promote greater survival in the CKD 
population; and discuss the clinical implications of the dual roles of obesity, including the 
obesity paradox, upon the management of CKD patients and future areas of research.
Obesity and Risk of Incident Chronic Kidney Disease
Epidemiologic studies
A growing body of evidence indicates that obesity is a potent risk factor for the development 
of de novo CKD and end-stage renal disease (ESRD) (Table 1 and Fig. 1) [10–12,14–18]. In 
a longitudinal analysis of 2585 participants in the Framingham Offspring Study cohort 
without preexisting kidney disease, incrementally higher BMI was associated with higher 
risk of developing CKD [defined as an estimated glomerular filtration rate (eGFR) <59 and 
<64ml/min/1.73m2 in men and women, respectively, based on the ‘Modification of Diet in 
Renal Disease formula’] over a mean follow-up of 19 years [adjusted odds ratio (95% 
confidence interval) 1.23 (1.08–1.41) per +1 SD of BMI] [10]. Subsequently, Hsu et al. [14] 
examined the association between BMI and risk of incident ESRD in one of the largest US 
studies of a multiracial population (among whom some had underlying CKD). Among more 
than 300000 patients in the Northern California Kaiser Permanente system whose medical 
information were linked with the United States Renal Data System (USRDS), the 
investigators found that those who were overweight or had class I, II, and extreme obesity 
(defined as BMI ranges of 25.0–29.9, 30.0–34.9, 35.0–39.9, and ≥40.0kg/ m2, respectively) 
had a 1.9, 3.6, 6.1, and 7.1-fold higher risk of developing ESRD compared with those of 
normal weight (BMI 18.0–24.9 kg/m2) independent of socio-demographics, comorbidities, 
and laboratory tests, including proteinuria. In a recent epidemiologic study of 3.4 million 
veterans with normal baseline kidney function [eGFR >60ml/min/1.73m2 based on the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] stratified by age 
Rhee et al. Page 2
Curr Opin Nephrol Hypertens. Author manuscript; available in PMC 2018 April 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and BMI, patients with obesity (defined by BMI > 30 kg/m2) experienced a faster decline in 
kidney function, particularly among older age groups, and those with BMI ranges more than 
35 kg/m2 also had higher mortality risk. Nevertheless, the most favorable kidney health 
outcomes were observed with overweight BMI ranges (25–30kg/m2) in this study [19▪].
Similar findings have been observed in large international cohorts with extended follow-up 
intervals. For example, among 105 611 Japanese adults with normal underlying kidney 
function who were stratified by sex, a graded association between higher BMI levels and 
risk of incident CKD was observed in both men and women (albeit at different BMI 
thresholds of more than 23.0 and 27.0 kg/m2, respectively) after a mean follow-up of 5 years 
[11]. In addition, Vivante et al. [18] examined ∼1.2 million Israeli adolescents (i.e., age 17 
years) examined for military service fitness whose medical data were linked to the national 
ESRD registry, and after a mean follow-up of 26 years, those who were overweight and 
obese (85th–95th and ≥95th percentiles of BMI, respectively) had a three and seven-fold 
higher risk of incident all-cause ESRD, independent of sex, country of origin, blood 
pressure, and enrollment period. However, these findings stand in contrast to a study of 185 
341 participants in an Austrian health monitoring program whose data were linked to the 
national dialysis and transplantation registry [17]. In this study, neither overweight nor obese 
body habitus (BMI levels 25–<30kg/m2 and ≥30kg/m2, respectively) were associated with a 
higher risk of incident ESRD after a mean follow-up interval of 18 years (reference: BMI 
18.5–<25.0kg/m2). Yet in a meta-analysis of 25 cohorts, three cross-sectional studies, and 19 
case-control studies by Wang et al. [12], pooled analyses showed that individuals who were 
overweight and obese (BMI 25.0–29.9 and ≥30.0kg/m2, respectively) had a higher risk of 
developing kidney disease ascertained by International Classification of Disease codes 
[hazard ratio (95% confidence interval) 1.40 (1.30–1.50) and 1.83 (1.57–2.13), respectively], 
with stronger associations observed in women vs. men. Finally, a recent meta-analysis by 
Ahmadi et al. [20▪] showed that, among patients with stages 3–5 CKD, higher BMI classes 
were associated with incrementally higher risk of progression to ESRD (Fig. 2) [21].
Emerging data also suggest that interventions targeted at reducing obesity may reverse or 
retard CKD progression. For example, in a large case series of 233 severely obese patients 
who underwent bariatric surgery, there was a statistically significant rise in mean eGFR 12 
months after surgery among those with obesity and CKD [22]. In another case series of 255 
morbidly obese patients with type 2 diabetes, reductions in BMI were associated with 
normalization of urine albumin-to-creatinine ratio levels 12 months following bariatric 
surgery [23].
Pathophysiologic mechanisms
Despite compelling epidemiologic evidence that excess body fat is a potent risk factor for 
kidney disease, the mechanisms involved in the pathogenesis of CKD in obesity have not 
been fully elucidated (Fig. 1). By increasing the risk of type 2 diabetes, hypertension, and 
atherosclerosis, excess fat mass may ‘indirectly’ lead to CKD [9,24]. Obesity may also have 
‘direct’ pathophysiological effects on the kidney via alterations in renal hemodynamics, 
inflammatory milieu, and growth factor and adipokine production [9,25]. For example, 
obesity may lead to mesangial expansion of the kidneys and increased renal metabolic 
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demand, resulting in glomerular hyperfiltration, hypertrophy, and hypertension, leading to 
increased glomerular filtration fraction, and subsequent glomerulosclerosis and proteinuria 
[9,25,26]. Indeed, focal segmental glomerulosclerosis has long been recognized as the 
hallmark lesion of obesity-related CKD [27].
There may be additional mechanisms by which obesity leads to de novo CKD. Adipocytes 
may directly synthesize proinflammatory and potentially proatherogenic cytokines such as 
TNF-α and IL-6 that may be implicated in the development of CKD [28,29]. Obesity also 
leads to greater production of the adipokine leptin, which has been shown to increase 
oxidative stress, sympathetic nervous system activity, glomerulosclerosis, renal fibrosis, and 
proteinuria [30]. Conversely, adiponectin has been shown to reduce podocyte dysfunction 
and permeability to albumin, and lower levels of this adipokine are typically observed in 
obesity [31]. However, as recent data suggest that higher adiponectin levels are 
paradoxically associated with a three-fold higher death risk in hemodialysis patients, 
independent of body composition and lipid levels, further study dissecting the impact of 
adipokines upon kidney health outcomes are needed [32]. In addition, excess fat may 
stimulate production of growth and hormonal factors that promote kidney damage, such as 
transforming growth factor-β and renin–angiotensin [9].
Obesity and Outcomes In The Chronic Kidney Disease Population
Whereas excess body fat appears to be a strong risk factor for the development and 
progression of kidney disease, some, but not all, studies suggest that obesity is associated 
with favorable outcomes (e.g., lower death risk) once CKD is acquired, particularly among 
those receiving hemodialysis (Fig. 3).
Nondialysis dependent chronic kidney disease patients
Although studies of BMI and mortality in NDD-CKD patients have shown mixed results, 
recent data in populations at high-risk for CKD suggest that these associations may be 
modified by age. In a study that examined the impact of age and BMI upon kidney function 
decline and mortality among a large cohort of US veterans with an eGFR greater than 60ml/ 
min/1.73m2 based on the CKD-EPI formula, primary analyses demonstrated a U-shaped 
association between BMI and mortality risk (i.e., BMI<25.0 and ≥30.0kg/m2 associated with 
higher mortality); however, upon adjustment for urine albumin-to-creatinine ratio, the higher 
BMI – higher mortality association was attenuated in older age groups but persisted in those 
of younger age [19▪].
When taken together, it also appears that the BMI-mortality association may vary according 
to underlying severity of CKD. In a study of 920 Swedish patients with advanced kidney 
dysfunction (i.e., stages 4–5 CKD), obesity (BMI > 30kg/m2) was associated with lower 
death risk [33]. Similarly in a study of 521 US veterans largely comprised of stages 3–5 
CKD patients, BMI levels exceeding the 50th percentile (BMI ≥ 28.1 kg/m2) predicted 
greater survival [34]. However, in studies of patients with moderate CKD (i.e., 
predominantly stages 3–4 CKD), Dalrymple et al. [35], Madero et al. [36], and Weiner et al. 
[37] did not observe a significant association between higher BMI and lower death risk. Yet 
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in a study inclusive of stage 1–2 CKD patients, Hsu et al. [14] found that higher BMI levels 
portended higher mortality risk, similar to that of the non-CKD population.
In light of these disparate findings, Ahmadi et al. [20▪] conducted a meta-analysis comprised 
of four studies of BMI and mortality in patients with stages 3-5 CKD. Pooled analyses, as 
well as reanalysis of the largest included study, demonstrated a reverse J-shaped association 
with death, such that those who were underweight had higher death risk and those of 
overweight and class I obesity body habitus had lower mortality (Fig. 2) [20▪,21]. In 
contrast, those with class II and III obesity had no association with death.
Maintenance hemodialysis patients
In contrast to the NDD-CKD population with mixed obesity – mortality findings, a 
consistent association between obesity and greater survival or lack of higher mortality has 
been observed in the hemodialysis population. The Diaphane collaborative study was the 
first to report that higher BMI was not associated with higher death risk among 1453 
nondiabetic hemodialysis patients recruited across 33 French dialysis clinics, which was 
confirmed in a study of 3607 USRDS patients by Leavey et al. [38,39]. Shortly thereafter, 
Fleischmann et al. [40] published the first study showing that overweight and obese 
hemodialysis patients had lower mortality risk, propelling the concept of the obesity paradox 
in the kidney disease population.
Following these studies, a number of large national and international hemodialysis cohort 
studies have similarly observed robust associations between higher BMI and lower mortality 
risk [41–44]. Although these prior studies have largely examined BMI at a single point-in-
time (i.e., baseline BMI ascertained at study entry), hemodialysis patients may frequently 
experience fluctuations in BMI resulting from changes in dietary intake, dialysis 
prescriptions, and comorbidity status. To account for these dynamic changes in BMI, in a 
recent study of more than 120 000 hemodialysis patients from a large national dialysis 
organization, Doshi et al. [45▪] examined the association between BMI as a time-varying 
exposure with all-cause mortality. Using a marginal structural model analysis to account for 
time-varying covariates (i.e., covariate that simultaneously functions as a confounder and 
intermediate of the BMI–mortality association), the investigators confirmed an inverse 
association between higher BMI and lower mortality risk, such that the lowest BMI category 
(BMI<18.0 kg/m2) was associated with a 3.2-fold higher death risk and the BMI category of 
40.0 to less than 45.0 kg/m2 was associated with the greatest survival (i.e., 31% lower death 
risk) as compared with the BMI reference of 25.0–27.5kg/m2. Finally, in a historic cohort 
study of 5904 incident hemodialysis patients recruited from 312 facilities across 15 
European countries over 2007–2009, inflammation ascertained by C-reactive protein levels 
was observed to an important modifier of the BMI–mortality association, such that higher 
BMI was associated with higher death risk among inflamed patients, whereas this 
association was mitigated in noninflamed patients [46▪].
Peritoneal dialysis patients
Studies of BMI and mortality in peritoneal dialysis patients have shown somewhat 
heterogeneous results. In a study of more than 40000 US incident peritoneal dialysis patients 
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by Snyder et al. [47], those of overweight and obese body habitus (BMI 25.0–29.9 and 
>30.0kg/m2) had greater survival compared with those of lower BMI. However, in a study of 
1675 hemodialysis and 1662 peritoneal dialysis patients from the USRDS Dialysis 
Morbidity and Mortality Wave II study conducted by Abbott et al. [48], BMI levels of at 
least 30.0 kg/m2 were associated with lower mortality in the hemodialysis cohort, but not in 
those receiving peritoneal dialysis. Similarly, in a study of 134 728 incident dialysis patients 
using the USRDS database, the lowest BMI quintile was associated with higher death risk in 
both hemodialysis and peritoneal dialysis patients; in contrast, the highest BMI quintile was 
associated with lower risk of death in hemodialysis patients but did not demonstrate a 
survival advantage in the peritoneal dialysis cohort [49].
A recent meta-analysis pooled four studies examining BMI and mortality in peritoneal 
dialysis patients, in which results were stratified according follow-up interval [50▪]. When 
follow-up was restricted to 1 year, investigators found that underweight body habitus was 
associated with higher death risk, whereas overweight and obese body habitus were 
associated with lower death risk; when follow-up intervals were extended to 2 and 3–5 
years, no association between BMI and mortality was observed.
Kidney transplantation recipients
There are considerable knowledge gaps surrounding the optimal BMI threshold for kidney 
transplantation eligibility, particularly in regards to avoidance of peri and postoperative 
complications. Although ‘posttransplantation obesity’ is known to be associated with higher 
risk of mortality and allograft failure [51], Molnar et al. [52] showed that, among 14 632 
wait-listed hemodialysis patients awaiting transplantation, each unit of higher 
‘pretransplantation BMI’ was associated with lower mortality, whereas weight loss 
increments of 3 to less than 5 kg and 5 kg or greater over 6 months were associated with 
higher mortality risk. Furthermore, past studies of pretransplantation obesity and 
posttransplantation mortality have shown mixed findings [53,54]. To address these 
uncertainties, a meta-analysis of four studies examining pretransplantation BMI upon 
posttransplantation outcomes, including mortality and allograft failure was conducted [55▪]. 
This study found that those of underweight, overweight, and obese body habitus had higher 
risk of death (reference: normal BMI class). Although underweight and obese body habitus 
were also associated with higher risk of graft failure, those who were overweight had similar 
risk as those of normal BMI. These findings did not support the presence of an obesity 
paradox in kidney transplantation recipients whose longevity is substantially increased 
compared with their hemodialysis counterparts. Hence, the investigators concluded that, in 
contrast to hemodialysis patients in whom the short-term benefits of obesity may outweigh 
its long-term risks, in kidney transplant recipients there may be sufficient time for obesity to 
lead to long-term adverse effects.
Other Metrics of Obesity
Although BMI is accepted as one of the most reliable anthropometric measures for obesity 
and is widely usedin research and clinical practice guidelines, it has limited ability in 
distinguishing between fat vs. muscle mass [7▪▪,56]. Although direct measurement of fat vs. 
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muscle mass in large epidemiologic studies may not be feasible, more accurate estimation of 
body composition and fat distribution in clinical practice and research are needed. For 
example, waist circumference and waist-to-hip ratio are known to be better indicators of 
visceral obesity in both the general and CKD populations, and emerging data indicate that 
these metrics are also potent predictors of adverse outcomes, including de novo CKD in 
those without underlying kidney disease, as well as incident ESRD and death risk in CKD 
patients [7▪▪,9,56–59]. Further research is needed to identify and refine practical methods of 
body composition assessment, to better ascertain the relationship between fat mass and 
outcomes in the CKD population.
Potential Mechanisms Underlying The Obesity Paradox
This paradoxically inverse association between higher BMI and lower mortality in CKD 
patients has also been observed in other chronic disease populations, including those with 
malignancy, HIV, congestive heart failure, type 2 diabetes, and emphysema [7▪▪,13,60,61]. 
Although there has been rather extensive scrutiny of the obesity paradox as being an artefact 
of survivor bias, reverse causation, or residual confounding, the strikingly robust 
associations across many studies of CKD and other chronic illness states and emerging data 
highlighting the putative beneficial effects of increased fat mass support this as a 
biologically plausible phenomenon (Table 2) [7▪▪,13,61–73].
Conclusion
Despite extensive past studies, there are substantial uncertainties regarding the clinical 
implications of obesity in the management of CKD patients [74]. For example, further 
research is needed to determine the causal factors engendering the obesity paradox, which 
will provide greater insight into its pathogenesis and consequences in other chronic disease 
populations. Given the heterogeneous associations between BMI and mortality in NDD-
CKD studies, future investigations are also needed to determine at which stage of kidney 
disease the obesity paradox develops, and which subpopulations of patients may be 
particularly susceptible. The therapeutic targets for BMI and body composition warrant 
more precise definition in NDD-CKD and dialysis patients, and in particular those 
participating in kidney transplantation (recipients and living donors). Lastly, given the 
compelling evidence for obesity as risk factor for incident CKD and ESRD, further studies 
are needed to determine the safety and effectiveness of weight loss interventions (e.g., 
pharmacologic, surgical, and physical activity) upon the development and progression of 
kidney disease.
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Key Points
• Obesity is highly prevalent among US adults, and has been associated with 
various comorbidities, including CKD.
• Obesity may lead to CKD via both indirect (type 2 diabetes, hypertension, 
metabolic syndrome, atherosclerosis) and direct mechanisms (glomerular 
hyperfiltration, inflammatory milieu, and altered growth factor and adipokine 
production).
• Once CKD is acquired, obesity is paradoxically associated with improved 
survival, particularly among those receiving hemodialysis, a phenomenon 
described as the ‘obesity paradox,’ in which short-term benefits of obesity 
may outweigh its long-term risks.
• However, recent pooled data do not confirm the presence of an obesity 
paradox in kidney transplantation recipients, whose longevity is 
comparatively longer than dialysis patients, and hence may have sufficient 
time for obesity to lead to long-term adverse effects.
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Figure 1. 
Potential pathways by which obesity leads to the development of chronic kidney disease. 
CKD, chronic kidney disease; DM, diabetes mellitus; ESRD, end-stage renal disease; GFR, 
glomerular filtration rate; RAS, renin–angiotensin– aldosterone system; TGF-β, 
transforming growth factor beta.
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Figure 2. 
Reanalysis of the largest study of BMI, progression to ESRD, and mortality in nondialysis 
dependent CKD patients by Lu et al. [21] Among patients with stages 3–5 CKD, higher BMI 
was associated with higher risk of incident ESRD, but obesity was paradoxically associated 
with survival advantage. Adapted from [20▪]. CKD, chronic kidney disease; ESRD, end-
stage renal disease.
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Figure 3. 
Dual roles of obesity as a risk factor for the development and progression of chronic kidney 
disease (CKD), as well as a predictor of greater survival among those with established 
kidney disease.
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Table 1
Selected studies of the association between higher BMI and incident chronic kidney 
disease and end-stage renal disease
Author (year) Cohort (N) Exposure definition Results Comments
Fox et al. [10] 
(2004)
Framingham Offspring cohort 
(2585)
BMI examined in 1-SD 
increments
Incrementally higher BMI 
associated with ↑ risk of 
incident CKD
N/A
Tsujimoto et al. 
[11] (2014)
Japanese participants (105 611) Fine gradations of BMI:
<18.5kg/m2
18.5–20.9 kg/m2
21.0–22.9 kg/m2
23.0–24.9 kg/m2
25.0–26.9 kg/m2
27.0-29.9 kg/m2
≥30.0kg/m2
Graded association between 
higher BMI and risk of 
incident CKD in analyses 
stratified by sex
BMI threshold 
for ↑
CKD risk:
Men: 23.0 
kg/m2
Women: 
27.0kg/m2
Hsu et al. [14] 
(2006)
Northern California Kaiser 
Permanente patients (320 252)
Overweight: 25.0–29.9 kg/m2
Class I obese: 30.0–34.9 
kg/m2
Class II obese: 35.0–39.9 
kg/m2
Morbidly obese: ≥40.0kg/m2
BMI levels >25.0kg/m2 
associated with ↑ risk of 
ESRD
Some patients 
had underlying 
CKD at study 
entry
Munkhaugen et 
al. [15] (2009)
Norwegian participants (74986) Overweight: 25.0–29.9 kg/m2
Class I obese: 30.0–34.9 
kg/m2
Class II/III obese: ≥35.0kg/m2
Among normotensive 
participants, those who had 
overweight, class I, and class 
II/III obesity did not have 
higher risk of ESRD and 
CKD-related death compared 
with those of normal weight 
(BMI 18.5–25.0 kg/m2) In 
contrast, among 
prehypertensive
participants, class I and II/III 
obesity were each associated 
with a higher risk of ESRD 
and CKD-related death 
compared with normal weight 
individuals
Blood pressure 
modifies the 
BMI – ESRD 
and death 
association
Panwar et al. [16] 
(2015)
REGARDS cohort (21840) Overweight: 25.0–29.9 kg/m2
Obese: ≥30.0kg/m2
Analyses stratified by weight 
and metabolic health
Overweight and obese 
individuals with the metabolic 
syndrome had a two and 2.3-
fold higher risk of developing 
ESRD, respectively, compared 
with those of normal weight 
(BMI 18.5–24.9 kg/m2) 
without the metabolic 
syndrome
Presence of the 
metabolic 
syndrome 
modifies the 
BMI – ESRD 
association
Pscheidt et al. 
[17] (2015)
Participants in an Austrian health 
monitoring program (185 341)
Overweight: 25–<30kg/m2
Obese: ≥30 kg/m2
No association between 
overweight and obese habitus 
with CKD
N/A
Vivante et al. [18] 
(2012)
Israeli adolescents examined for 
military service fitness (1194 704)
Overweight: 85th–95th BMI 
percentile
Obese: ≥95th BMI percentile
Overweight and obese habitus 
associated with ↑ risk of 
ESRD
N/A
CKD, chronic kidney disease; ESRD, end-stage renal disease; REGARDS, Reasons for Geographic and Racial Differences in Stroke study.
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Table 2
Proposed explanatory factors underlying the obesity paradox
Mechanism Pathways by which obesity may reduce mortality risk
Time-discrepancy between competing risk 
factors for death (undernutrition vs. 
overnutrition) [7▪▪,13]
Given shortened lifespan of dialysis patients, short-term benefits of overnutrition overrides 
long-term risks of obesity
Reverse causation [7▪▪,13] Lower BMI is not the cause but rather the sequelae of comorbidities/conditions leading to 
higher mortality in CKD patients
Survivor bias [7▪▪,13] Majority of CKD patients will die prior to developing ESRD, and the resultant ESRD 
population represents a selected cohort
Observed associations between mortality predictors in ESRD survivors may not be 
generalizable to the greater CKD population
PEW [7▪▪,13,61] Greater metabolic reserve during periods of deficient energy and protein intake reduce risk 
of developing PEW
Excess fat and protein stores may reduce susceptibility to infection and other inflammatory 
processes
Weight loss may lead to reduced skeletal muscle oxidative metabolism and mitigated 
antioxidant defense
Alteration of circulating cytokines [62–65] Favorable alterations in TNF-α system:
In ESRD patients TNF-α is elevated and contributes to cardiac injury via proapoptotic and 
negative inotropic effects
Adipose tissue produces soluble TNF-α receptors that neutralize adverse biologic effects of 
TNF-α
Favorable genetic variants/ expression [66–68] Genetic variant of a-2-Heremans-Schmid glycoprotein that is associated with lower fetuin-A 
levels is more common in lean vs. obese patients
Obese patients have higher levels of fetuin-A, reducing their genetic predisposition to 
vascular calcification
In obese patients with renal cell cancer, there is differential gene expression of metabolic and 
fatty acid genes vs. normal weight patients that may contribute to the obesity paradox in 
malignancy
More stable hemodynamic status [7▪▪,
13,63,69]
Overweight/obese dialysis patients with heart failure have higher systolic blood pressure 
values (even in the context of similar pulmonary capillary wedge pressures and cardiac 
indices)
Higher tolerance of large ultrafiltration volumes, less intra and postdialytic hypotension, and 
myocardial stunning
Endotoxin–lipoprotein interaction [70] Obese patients have higher lipid and lipoprotein concentrations
Lipoproteins can bind and remove circulating endotoxins, subsequently reducing effects of 
inflammation, atherosclerosis, etc.
Uremic toxin sequestration [7▪▪,71] Adipose tissue sequesters uremic toxins
Weight loss and loss of fat mass may result in release of lipophilic hexachlorobenzene and 
other chlorinated hydrocarbons
Neurohormonal alterations [72,73] Lean patients may have heightened sympathetic nervous system and renin-angiotensin 
activity vs. obese patients
CKD, chronic kidney disease; ESRD, end-stage renal disease; PEW, protein-energy wasting.
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